RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive|HER2/Neu Negative|Male Breast Carcinoma|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: Exemestane|DRUG: Gamma-Secretase Inhibitor RO4929097|DRUG: Goserelin Acetate
Sponsor: National Cancer Institute (NCI)